Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2052W HIGH $2.37
Volume
1.22 M
Value Traded
470.35 K
Short % Float
1.93%
-9.82%Week
+43.05%1 Month
+9%3 Month
+9.34%6 Month
-91.52%5 Year
-94.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
55.88 M
EPS (TTM)
-0.18
P/E Ratio
-
Ent. Value
25.76 M
Total Shares
159.62 M
Float Shares
159.62 M
Insiders
0.00%
Institutions
36.09%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MREO Catalyst Timeline
Dated clinical, regulatory and corporate events for Mereo BioPharma Group plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Mereo BioPharma Group plc
411Total events
4Upcoming
109Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseAlvelestatCorporate
Sentynl and Mereo enter option and license agreement for alvelestat in AATD-LD
Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)source ↗
◆Full ResultssetrusumabClinical Data
Further analyses of data from Cosmic Phase 3 study completed
osteogenesis imperfectasource ↗
◆FDA Feedback ReceivedsetrusumabFDA Meeting
Initiated regulatory interactions with agencies for setrusumab in pediatric OI
osteogenesis imperfectasource ↗
◆Partnership / LicenseAlvelestatCorporate
Engaged in discussions with potential partners for alvelestat Phase 3 development
alpha-1 antitrypsin deficiency-associated lung diseasesource ↗
▲Trial InitiationVantictumabTrial
shibio plans to initiate Phase 2 trial of vantictumab in ADO2
autosomal dominant osteopetrosis Type 2source ↗
◆Additional DatasetrusumabClinical Data
Additional data analyses from Orbit and Cosmic Phase 3 studies ongoing
osteogenesis imperfectasource ↗
◆Oral PresentationPresentation
Dr. Denise Scots-Knight presents at 44th Annual J.P. Morgan Healthcare Conference
◆Oral PresentationsetrusumabPresentation
Data from Phase 3 Orbit and Cosmic studies presented at J.P. Morgan Healthcare Conference
osteogenesis imperfectasource ↗
▼Primary Endpoint MissedClinical Data
COSMIC Phase 3 study did not meet primary endpoint of reduction in annualized clinical fracture rate
osteoporosissource ↗
▼Primary Endpoint MissedsetrusumabClinical Data
COSMIC Phase 3 study missed primary endpoint of reduction in annualized clinical fracture rate
Osteogenesis Imperfectasource ↗
▼Trial DiscontinuedTrial
COSMIC Phase 3 study did not meet primary endpoint
fracture reductionsource ↗
▲Secondary Endpoint DatasetrusumabClinical Data
COSMIC achieved secondary endpoint of improvements in bone mineral density with strong statistical significance
Osteogenesis Imperfectasource ↗
▼Program DiscontinuationsetrusumabCorporate
Immediate reductions in pre-commercial and manufacturing activities for setrusumab
Osteogenesis Imperfectasource ↗
▼Topline ReadoutsetrusumabClinical Data
Phase 3 Cosmic study of setrusumab did not achieve statistical significance on primary endpoint
osteogenesis imperfectasource ↗
▲Primary Endpoint MetsetrusumabClinical Data
Cosmic achieved high statistical significance on key secondary endpoint of BMD improvement
osteogenesis imperfectasource ↗
◆Topline ReadoutsetrusumabClinical Data
Topline data from Phase 3 Cosmic study of setrusumab in OI
osteogenesis imperfectasource ↗
◆Topline ReadoutsetrusumabClinical Data
Final analysis data from Phase 3 Cosmic study expected around year-end 2025
osteogenesis imperfectasource ↗
◆Trial CompletionsetrusumabTrial
Potential final analysis of Phase 3 Orbit study of setrusumab in OI expected Q4 2025
osteogenesis imperfectasource ↗
▲Interim AnalysissetrusumabTrial
DMC interim analysis of Phase 3 Orbit study confirms acceptable safety profile, study to continue
osteogenesis imperfectasource ↗
◆Interim AnalysissetrusumabTrial
Second interim analysis of Phase 3 Orbit study of setrusumab in OI expected mid-2025
osteogenesis imperfectasource ↗
▲Milestone PaymentleflutrozoleCorporate
One-time milestone payment received for clinical milestone on leflutrozole
infertility in men with low testosteronesource ↗
◆Oral PresentationPresentation
Fireside chat at Leerink Partners Global Healthcare Conference
◆Oral PresentationPresentation
Mereo BioPharma to present at 43rd Annual J.P. Morgan Healthcare Conference
▲EU Orphan DesignationAlvelestatEx-US Regulatory
Positive EMA COMP opinion for orphan designation of alvelestat
alpha-1 antitrypsin deficiency-associated lung diseasesource ↗
▲EU Orphan DesignationAlvelestatEx-US Regulatory
European Commission granted Orphan Designation for alvelestat
Alpha-1 Antitrypsin Deficiency-associated Lung Diseasesource ↗
▲CHMP Positive OpinionAlvelestatEx-US Regulatory
EMA Committee for Orphan Medicinal Products positive recommendation for alvelestat
Alpha-1 Antitrypsin Deficiency-associated Lung Diseasesource ↗
▲Partnership / LicenseVantictumabCorporate
Partnership with āshibio for vantictumab; Mereo retains EU/UK rights
autosomal dominant osteopetrosis type 2source ↗
●Poster PresentationVantictumabPresentation
Preclinical data presented at ASBMR Annual Meeting
autosomal dominant osteopetrosis type 2source ↗
▲Enrollment CompletesetrusumabTrial
Enrollment completed in Phase 2/3 pivotal study in pediatrics and young adults (5-25 years)
osteogenesis imperfectasource ↗
▲FDA Feedback ReceivedAlvelestatFDA Meeting
Aligned with FDA and EMA on primary endpoints for Phase 3 pivotal study
alpha-1 antitrypsin deficiency-associated lung diseasesource ↗
◆Topline ReadoutsetrusumabClinical Data
Topline data from Phase 3 Orbit study expected in 2025
osteogenesis imperfecta (OI)source ↗
◆Trial InitiationAlvelestatTrial
Plans to initiate Phase 3 global pivotal study with a partner around end of 2024
Alpha-1 Antitrypsin Deficiency-associated Lung Diseasesource ↗
◆Timing GuidanceAlvelestatPresentation
AATD program to be Phase 3-ready by end of 2024
alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)source ↗
◆Oral PresentationPresentation
Mereo BioPharma to participate in Fireside Chat at Jefferies London Healthcare Conference
▲Breakthrough Therapy DesignationsetrusumabDesignation
Setrusumab received Breakthrough Therapy designation from FDA
osteogenesis imperfecta (OI) Type I, III, or IVsource ↗
Past FDA Catalysts and PDUFA Decisions
How MREO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Setrusumab | Phase 2/3 data readout | Phase 2/3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C41 / 100
Pipeline Score
$11M
Pipeline Value
Overvalued
Valuation Signal
8
Drugs Scored
0.2x
rNPV / MCap
Top 38%
Micro Cap(rank 251 of 660)
Percentile Rank
Mereo BioPharma Group plc carries a moderate pipeline score (41/100), with $1.3B risk-adjusted pipeline value, led by Etigilimab in Solid Tumor, Adult (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Etigilimab Monoclonal antibodyCompletedNCT04761198 | Solid Tumor, Adult | Phase 2 | COMPLETED | 76 | Oct 1, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every MREO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| setrusumab Breakthrough | osteogenesis imperfecta | Phase 3 | 2026-03-19 | statistically significant improvements in bone mineral density; compelling reductions in vertebral fractures; statistically significant improvements in PROs of disease pain and daily activity in pediatric and teenage patientsRead More | Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Scots-Knight DeniseDirector, Officer (Chief Executive Officer) | Sell | -60,046 808,921 held | $4.22 | 09/13/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in MREO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 0 % (-100 %) | 317.00 K | 1.00 M | -92.52% ( -12.37 M) |
MREO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MREO ranks across every disease it competes in
Competitive Position is a premium feature
See how MREO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMREO News
MREO▲ +12.2%on this news
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Mereo BioPharma reported its Q2 2026 financial results, highlighting a partnership with Sentynl Therapeutics for alvelestat and ongoing regulatory discussions for setrusumab. The company has approximately $30 million in cash, expected to fund operations into late 2027. Despite challenges in achieving primary endpoints in clinical trials, Mereo remains optimistic about its product candidates.
Read more →MREO▲ +12.2%on this news
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Sentynl Therapeutics and Mereo BioPharma have entered into an option and license agreement for alvelestat, a potential first-in-class oral treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD). Sentynl will have U.S. commercialization rights while Mereo leads global development. The agreement includes funding for Phase 3 trials, which are expected to start in early 2027.
Read more →MREOMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Mereo BioPharma reported its Q1 2026 financial results, highlighting ongoing clinical developments. The company is engaging with regulatory agencies regarding setrusumab for pediatric osteogenesis imperfecta. Alvelestat is poised to enter Phase 3 development, while vantictumab is set for a Phase 2 trial in osteopetrosis. The financial outlook remains stable with a cash position of $36.2 million.
Read more →MREOMereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
Mereo BioPharma reported its financial results for the full year 2025, highlighting ongoing analyses from the Phase 3 studies of setrusumab for osteogenesis imperfecta. Although primary endpoints were not met, secondary endpoints demonstrated significant improvements in bone mineral density. The company is actively pursuing partnerships for a Phase 3 study of alvelestat while its revised financial roadmap now supports operations into mid-2027. However, the company reported a net loss and a decrease in cash reserves, which may pose challenges moving forward.
Read more →MREO▲ +14.7%on this news· ran to +36% by day 3
Mereo BioPharma Provides Corporate Update
Mereo BioPharma recently provided a corporate update regarding its pipeline and financial situation. The company continues to analyze data from the Phase 3 Orbit and Cosmic studies of setrusumab for osteogenesis imperfecta, despite not achieving statistical significance in primary endpoints. Mereo's cash reserves are projected to fund operations until mid-2027, highlighting its financial stability. Additionally, discussions for potential partnerships for its programs, including alvelestat for alpha-1 antitrypsin deficiency, are ongoing.
Read more →MREO▼ -87.6%on this newsshared move
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
Mereo BioPharma announced that its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta did not meet their primary endpoints of reducing clinical fracture rates. However, both studies showed significant improvements in bone mineral density. The company plans to conduct further analyses to determine the next steps for the program, especially in pediatric patients.
Read more →MREO▲ +5.6%on this news
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
Mereo BioPharma reported its Q3 2025 financial results, highlighting progress in Phase 3 studies of setrusumab for osteogenesis imperfecta, expected to conclude by the end of 2025. The company has $48.7 million in cash, projected to fund operations through 2027. Despite a net loss of $7.0 million, Mereo remains optimistic about its product pipeline and commercial readiness.
Read more →MREO▲ +9.2%on this news
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
Mereo BioPharma reported its Q2 2025 financial results, highlighting its ongoing clinical studies for setrusumab in osteogenesis imperfecta and plans for alvelestat in AATD-lung disease. The company has a solid cash position to support operations until 2027, amid recent announcements regarding upcoming data from pivotal trials. While it demonstrated increased R&D expenses, Mereo maintains optimism due to the potential impact of its product candidates and ongoing discussions for potential partnerships.
Read more →MREO▼ -7.2%on this news
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
Mereo BioPharma reported its first quarter 2025 financial results, highlighting the ongoing Phase 3 Orbit study for setrusumab in osteogenesis imperfecta. As of March 31, 2025, the company holds $62.5 million in cash, which is anticipated to fund operations into 2027. The company is also preparing for a potential launch of setrusumab in Europe and is advancing alvelestat towards a Phase 3 pivotal study after receiving Orphan Designation from the European Commission. Despite these developments, Mereo reported a net loss of $12.9 million for the quarter.
Read more →MREOMereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025
Mereo BioPharma reported its financial results for the full year 2024 and outlined significant advancements in its clinical studies. The Phase 3 Orbit study for setrusumab in osteogenesis imperfecta is progressing towards a second interim analysis expected in mid-2025. Additionally, alvelestat received Orphan Designation from the European Commission for treating alpha-1 antitrypsin deficiency-associated lung disease. The company reported a net loss of $43.3 million while maintaining a strong cash position that supports operations into 2027.
Read more →MREOMereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
Mereo BioPharma announced that CEO Dr. Denise Scots-Knight will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 12, 2025. The company focuses on developing therapeutics for rare diseases, with key candidates including setrusumab and alvelestat. Mereo's partnerships and designations from regulatory bodies highlight its commitment to innovation in the biopharmaceutical sector.
Read more →MREO▼ -5.9%on this news· ran to -18% by day 3
Mereo BioPharma Provides Update on Lead Clinical Programs
Mereo BioPharma has provided updates on its lead clinical programs, including the Phase 3 Orbit study of setrusumab for osteogenesis imperfecta, which is progressing towards a second interim analysis expected in mid-2025. Additionally, alvelestat received a positive opinion for European Orphan Designation, with a final decision anticipated in early 2025. The company maintains a strong cash position to support operations through 2027.
Read more →MREOMereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Mereo BioPharma will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The company focuses on developing therapeutics for rare diseases, with notable candidates including setrusumab and alvelestat. Mereo's partnerships and designations from regulatory bodies highlight its commitment to advancing its product pipeline.
Read more →MREO▼ -5.7%on this news
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Mereo BioPharma Group plc (NASDAQ: MREO) announced that Dr. Denise Scots-Knight, CEO, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on November 19, 2024. The event aims to address their advancements and strategies in the rare diseases sector. Investors can access a live audio webcast of the presentation through the company's website, and an archived replay will be available for two weeks following the event.
Read more →MREOMereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of
Mereo BioPharma reported its financial results for Q3 2024, highlighting significant developments including the FDA's Breakthrough Therapy designation for setrusumab, targeting osteogenesis imperfecta. The company has $80.5 million in cash reserves, expected to sustain operations into 2027. Despite an increase in net loss primarily due to foreign exchange impacts, the Phase 3 programs for setrusumab and alvelestat remain on track for further advancements. The company continues to establish its presence in key European markets with ongoing pre-commercial activities.
Read more →MREO▼ -5.8%on this news
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
Mereo BioPharma Group plc announced that its CEO, Dr. Denise Scots-Knight, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on September 18, 2024. The live audio webcast will be accessible via the company's investors section on their website. Mereo is focused on developing treatments for rare diseases, with notable progress in candidate products such as setrusumab and alvelestat. The company has ongoing partnerships and has received various designations for its products from regulatory agencies.
Read more →MREOMereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2
Mereo BioPharma reported its second quarter 2024 financial results, highlighting significant advances in its clinical studies for setrusumab in osteogenesis imperfecta (OI), with a documented 67% reduction in fracture rates. The company has secured $87.4 million in cash, projected to sustain operations through 2027. Mereo continues to prepare regulatory submissions for its alvelestat program to ensure compliance for Phase 3 readiness by year's end. However, R&D expenses have noticeably increased, leading to a higher net loss this quarter compared to last year.
Read more →MREO▲ +6.5%on this news
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market London
Mereo BioPharma has announced the pricing of an underwritten registered direct offering of 12,531,300 American Depositary Shares at a price of $3.99 each, aiming to raise approximately $50 million. The funds will primarily be allocated to support the setrusumab program and general corporate purposes. The offering, expected to close around June 17, 2024, includes participation from several institutional investors. This offering helps bolster the company’s financial position as it progresses with its clinical development plans for rare disease therapies.
Read more →MREOUltragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfect
Ultragenyx and Mereo BioPharma have announced positive results from the Phase 2 portion of their Orbit study, indicating that treatment with setrusumab (UX143) led to a significant 67% reduction in annualized fracture rates among patients with Osteogenesis Imperfecta. After 14 months of treatment, continued improvements in bone mineral density were noted, with a mean increase of 22%. No serious adverse events related to the treatment were observed, and further data presentations are anticipated in the future.
Read more →About Mereo BioPharma Group plc
HeadquartersONE CAVENDISH PLACE, LONDON, W1G 0QF
BIOPHARMAWATCH ELITE PLUS
Trade the next MREO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime